School of Medicine, Case Western Reserve University, Cleveland, Ohio.
Department of Dermatology, Cleveland Clinic, Cleveland, Ohio; Jacksonville Skin Cancer Specialists, Jacksonville, Florida.
J Am Acad Dermatol. 2021 Mar;84(3):719-724. doi: 10.1016/j.jaad.2020.08.083. Epub 2020 Aug 27.
Information about the frequency and timing of subsequent cutaneous squamous cell carcinoma (cSCC), along with associated risk factors, is limited. However, this information is crucial to guide follow-up care for these patients.
To evaluate the risk and timing of subsequent cSCC in patients who presented with an initial diagnosis of cSCC.
Retrospective review of an institutional review board-approved, single-institution registry of invasive cSCC. All patients had at least 2 primary cSCCs diagnosed on 2 separate dates 2 months apart.
A total of 299 primary cSCCs were included. At 6 months from initial cSCC diagnosis, 18.06% (n = 54) of patients developed subsequent cSCC; at 1 year, 31.77% (n = 94); at 3 years, 67.56% (n = 202); and at 5 years, 87.96% (n = 263) developed subsequent cSCC. Risk factors associated with subsequent cSCC include age at initial diagnosis (hazard ratio [HR], 1.02; 95% confidence interval, 1.004-1.027; P = .008), T2 stage (HR, 1.66; 95% CI, 1.07-2.57; P = .025), and poor tumor grade. Tumor grades well, moderate, and unknown have HRs of 0.21 (P < .001), 0.16 (P .001), and 0.25 (P = .001), respectively.
Of patients who develop subsequent cSCC, 18.06% do so within 6 months, and 31.77% do so within 1 year of initial cSCC diagnosis. Patients with advanced age, poor histologic differentiation, and American Joint Committee on Cancer T2 stage are at highest risk. Close clinical follow-up after the initial diagnosis is recommended.
关于继发皮肤鳞状细胞癌(cSCC)的频率和时间,以及相关风险因素的信息有限。然而,这些信息对于指导这些患者的随访护理至关重要。
评估初诊为 cSCC 的患者继发 cSCC 的风险和时间。
回顾性审查机构审查委员会批准的单机构侵袭性 cSCC 登记处。所有患者至少有 2 次原发性 cSCC 诊断,间隔 2 个月。
共纳入 299 例原发性 cSCC。在初次诊断为 cSCC 后的 6 个月时,18.06%(n=54)的患者发生了继发 cSCC;1 年后为 31.77%(n=94);3 年后为 67.56%(n=202);5 年后为 87.96%(n=263)。与继发 cSCC 相关的风险因素包括初始诊断时的年龄(风险比[HR],1.02;95%置信区间,1.004-1.027;P=.008)、T2 期(HR,1.66;95%CI,1.07-2.57;P=.025)和肿瘤分级差。肿瘤分级良好、中度和未知的 HR 分别为 0.21(P<.001)、0.16(P<.001)和 0.25(P=.001)。
在继发 cSCC 的患者中,18.06%在初次诊断后 6 个月内发生,31.77%在 1 年内发生。年龄较大、组织学分化差和美国癌症联合委员会 T2 期的患者风险最高。建议在初次诊断后进行密切的临床随访。